4-(2-Methylpropanoylamino)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-Methylpropanoylamino)benzamide
• 化学式: C₁₁H₁₄N₂O₂
• mdl: MFCD00752465
• 分子量: 206.24
• InChiKey: BHSUIPKWPNKXAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS
  申请人：CARLINI Rina

  公开号：US20100035172A1

  公开（公告）日：2010-02-11

  A nanoscale pigment particle composition includes an organic benzimidazolone pigment, and a sterically bulky stabilizer compound, wherein the benzimidazolone pigment associates non-covalently with the sterically bulky stabilizer compound that is an alkylated-benzimidazolone compound; and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale pigment particles.

  一种纳米级颜料粒子组合物包括有机苯并二唑酮颜料和立体障碍稳定剂化合物，其中苯并二唑酮颜料与立体障碍稳定剂化合物非共价结合，该化合物是烷基化苯并二唑酮化合物；并且所述稳定剂的存在限制了颗粒生长和聚集的程度，从而得到纳米级颜料粒子。
• MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Nishida Hidemitsu

  公开号：US20110059958A1

  公开（公告）日：2011-03-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下式（I）所描述的化合物，或其药学上可接受的盐或溶剂。本发明还提供了包含一种或多种所述化合物的制药组合物，并使用该化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。
• PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE
  申请人：Aicher Babette

  公开号：US20100234377A1

  公开（公告）日：2010-09-16

  The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing. Certain compounds of general formula (I) are new and the invention also relates to these compounds and to their use in medicine.

  本发明涉及一般式（I）的化合物：其中A、Y、X、n和B如此定义；以及它们在治疗和预防代谢紊乱、炎症病症、过敏症、发热、疼痛（包括触觉过敏和痛觉敏感）、进食障碍、消瘦症、脑损伤、生殖器癌症、睡眠呼吸暂停、心血管疾病、烟酸及相关化合物引起的潮红反应或促进伤口愈合方面的用途。某些一般式（I）的化合物是新的，本发明还涉及这些化合物及其在医学上的应用。
• NONPOLAR LIQUID AND SOLID PHASE CHANGE INK COMPOSITIONS COMPRISING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS
  申请人：Carlini Rina

  公开号：US20100319573A1

  公开（公告）日：2010-12-23

  An ink composition, such as a nonpolar liquid or phase change (solid) ink composition, that includes a non-polar carrier, and a nanoscale pigment particle composition. The nanoscale pigment particle composition includes a benzimidazolone pigment and a sterically bulky stabilizer compound, which is an alkylated derivative of an aromatic acid, associated non-covalently with the benzimidazolone pigment. The presence of the associated stabilizer limits an extent of particle growth and aggregation, to afford nanoscale pigment particles.

  一种墨水组成物，例如非极性液体或相变（固体）墨水组成物，包括非极性载体和纳米颜料粒子组成物。纳米颜料粒子组成物包括苯并咪唑酮颜料和一个大体积的立体阻碍剂化合物，它是一种芳香酸的烷基衍生物，与苯并咪唑酮颜料非共价结合。存在关联稳定剂限制颗粒生长和聚集的程度，以获得纳米颜料粒子。
• METHODS OF MAKING NANOSIZED PARTICLES OF BENZIMIDAZOLONE PIGMENTS
  申请人：CARLINI Rina

  公开号：US20100004360A1

  公开（公告）日：2010-01-07

  Nanoscale particles of benzimidazolone pigments are made by providing one or more organic pigment precursor(s) to a benzimidazolone pigment, providing a solution or suspension of a sterically bulky stabilizer compound that associates non-covalently with a benzimidazolone moiety on one of the pigment precursors, wherein the sterically bulky stabilizer compound is selected from the group consisting of substituted pyridine derivatives, alkylated benzimidazolone compounds, alkylated derivatives of aromatic acids, and mixtures thereof, and carrying out a coupling reaction to form a benzimidazolone pigment composition, whereby one or more functional moieties on the benzimidazolone pigment is non-covalently associated with the sterically bulky stabilizer, so as to limit an extent of particle growth and aggregation and results in nanoscale pigment particles.